|
NSABP B-37/IBCSG 27-02
A Randomized Clinical Trial of Adjuvant Chemotherapy For Radically Resected Loco-Regional Relapse of Breast Cancer
NSABP B-39 A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women with Stage 0, I, or II Breast Cancer (Open, enrollment via radiation oncology)
NSABP B-40 A Randomized Phase III Trial of Neoadjuvant Therapy in Patients with Palpable and Operable Breast Cancer Evaluating the effects on Pathologic Complete Response (pCR) of Adding Capecitabine or Gemcitabine to Docetaxel when Administered Before AC with or without Bevacizumab and Correlative Science Studies Attempting to Identify Predictors of High Likelihood for pCR with Each of the Regimens
NSABP B-41 A Randomized Phase III Trial of Neoadjuvant Therapy for Patients with Palpable and Operable HER2 Positive Breast Cancer Comparing the Combination of Trastuzumab Plus Lapatinib
Administered with Weekly Paclitaxel Following AC accompanied
by Correlative Science Studies to Identify Predictors of
Pathologic Complete Response.
NSABP B-42 A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in
Postmenopausal Women with Hormone Receptor Positive Breast
Cancer (B-44 Optional Registration Program Closed Sept 2008)
NSABP B-44-I (The Beth Trial): A Multicenter Phase III Randomized Trial of Adjuvant
Therapy for Patients with HER-2 Positive Node-Positive or High Risk Node Negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab with Chemotherapy Plus Trastuzumab Plus Bevacizumab
STUDY #0502: “Thyroid function and breast cancer: A pilot study to estimate the prevalence of thyroid dysfunction in women diagnosed with breast cancer and the magnitude of change in thyroid function post-chemotherapy
PACCT-1: Program for the Assessment of Clinical Cancer Tests: TailoRx - Trials Assigning Individualized Options for Treatment
ECOG 5103: A Double-Blind Phase III Trial of Doxorubicin and
Cyclophosphamide Followed by Paclitaxel with Bevacizumab or
Placebo in Patients with Lymph Node Positive and High Risk
Lymph Node Negative Breast Cancer
ECOG 5204: Intergroup Randomized Phase III Study of Postoperative
Oxaliplatin, 5-Fluouracil and Leucovorin VS Oxaliplatin, 5-Fluouracil, Leucovorin and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Pre-operative Chemoradiation
NSABP R-04 A Clinical Trial Comparing Preoperative Radiation Therapy and
Capecitabine with Preoperative Radiation Therapy and Continuous Intravenous Infusion (CVI) of 5-Fluorouracil (5-FU) in the Treatment of Patients with Operable Carcinoma of the Rectum
CALGB –SWOG C80405: A Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin with Bevacizumab or Cetuximab (C225), or with the Combination of Bevacizumab and Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum (HOLD)
CALGB – C80403/E1206: Randomized Phase II Study of ECF-C, IC-C, or FOLFOX-C in Metastatic Esophageal and GE Junction Cancer
E1505 : A phase III randomized trial of adjuvant chemotherapy with or without
Bevacizumab for patients with completely resected stage 1B(>4cm)-IIIA non-small cell lung cancer (NSCLC)
HLMCC 0501 Stress Management – Usual psychosocial care vs. self administered stress
management plus usual psychosocial care
***HISPANIC PARTICIPANTS ONLY***
NON-HISPANIC ENROLLMENT COMPLETE
C05009: Randomized Phase IIIB Study of Three Treatment Regimens in Subjects
with Previously Untreated Multiple Myeloma Who are not Considered
Candidates for High-Dose Chemotherapy and Autologous Stem Cell
Transplantation: Velcade (Bortezomib), Thalidomide and Dexamethasone
(VTD) Versus Velcade and Dexamethasone (VD) Versus Velcade,
Melphalan and Prednisone (VMP) (PHARMACEUTICAL SPONSORED)
ECOG 3404: Response-Adapted Therapy for Aggressive Non-Hodgkin’s Lymphomas Based
on Early FDG – PET Scanning: Rituximab and Combination Chemotherapy in Treating Patients with Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non Hodgkin’s Lymphoma
|
